Subsequently, we used IPS to predict the immunotherapeutic response of BLCA patients who received different treatment modalities (such as no treatment, anti-CTLA4, anti-PD1/PD-L1/PD-L2, or combination therapy). This evidence concerns the gene CD274 and bladder transitional cell carcinoma.